CoChat

ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer

Open access
Li, Zhuqing, Zhou, Wei, Zhang, Yi, Sun, Wei, Yung, Mingo M.H., Sun, Jing, Li, Jing, Chen, Chi-Wei, Li, Zongzhu, Meng, Yunxiao, Chai, Jie, Zhou, Yuan, Liu, Stephanie S., Cheung, Annie N.Y., Ngan, Hextan Y.S., Chan, David W., Zheng, Wei, Zhu, Wenge · 2019 · Clinical Cancer Research
Cited by 48

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Purpose: Up to 80% of patients with ovarian cancer develop platinum resistance over time to platinum-based chemotherapy. Increased HIF1α level is an important mechanism governing platinum resistance in platinum-resistant ovarian cancer (PROC). However, the mechanism regulating HIF1α stability in PROC remains largely unknown. Here, we elucidate the mechanism of HIF1α stability regulation in PROC and explore therapeutic approaches to overcome cisplatin resistance in ovarian cancer. Experimental Design: We first used a quantitative high-throughput combinational screen (qHTCS) to identify novel drugs that could resensitize PROC cells to cisplatin. Next, we evaluated the combination efficacy of inhibitors of HIF1α (YC-1), ERK (selumetinib), and TGFβ1 (SB431542) with platinum drugs by in vitro and in vivo experiments. Moreover, a novel TGFβ1/ERK/PHD2-mediated pathway regulating HIF1α stability in PROC was discovered. Results: YC-1 and selumetinib resensitized PROC cells to cisplatin. Next, the prolyl hydroxylase domain-containing protein 2 (PHD2) was shown to be a direct substrate of ERK. Phosphorylation of PHD2 by ERK prevents its binding to HIF1α, thus inhibiting HIF1α hydroxylation and degradation—increasing HIF1α stability. Significantly, ERK/PHD2 signaling in PROC cells is dependent on TGFβ1, promoting platinum resistance by stabilizing HIF1α. Inhibition of TGFβ1 by SB431542, ERK by selumetinib, or HIF1α by YC-1 efficiently overcame platinum resistance both in vitro and in vivo. The results from clinical samples confirm activation of the ERK/PHD2/HIF1α axis in patients with PROC, correlating highly with poor prognoses for patients. Conclusions: HIF1α stabilization is regulated by TGFβ1/ERK/PHD2 axis in PROC. Hence, inhibiting TGFβ1, ERK, or HIF1α is potential strategy for treating patients with PROC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-4145

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 48

Metadata

Authors
Li, Z., Zhou, W., Zhang, Y., Sun, W., Yung, M. M. H., Sun, J., Li, J., Chen, C.-W., Li, Z., Meng, Y., Chai, J., Zhou, Y., Liu, S. S., Cheung, A. N. Y., Ngan, H. Y. S., Chan, D. W., Zheng, W., & Zhu, W.
Venue
Clinical Cancer Research
Published
2019-10-01
Volume
25
Issue
19
Pages
5947-5960
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2959887563
Cited by
48
References
13
FWCI
2.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-4145
The paper
Li, Z., Zhou, W., Zhang, Y., Sun, W., Yung, M. M. H., Sun, J., Li, J., Chen, C.-W., Li, Z., Meng, Y., Chai, J., Zhou, Y., Liu, S. S., Cheung, A. N. Y., Ngan, H. Y. S., Chan, D. W., Zheng, W., & Zhu, W. (2019). ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-4145

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.